Aigen Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Aigen Investment Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,732	Closed	-$240K	–	1029
2023 Q3	$240K	Buy	6,732 +2,312	+52%	+$91.6K	0.05%	605
2023 Q2	$204K	Buy	+4,420	New	+$205K	0.03%	616
2022 Q2	–	Sell	-13,982	Closed	-$1.01M	–	693
2022 Q1	$1.01M	Buy	+13,982	New	+$973K	0.18%	158
2021 Q3	–	Sell	-7,478	Closed	-$713K	–	625
2021 Q2	$713K	Buy	7,478 +5,499	+278%	+$573K	0.12%	179
2021 Q1	$225K	Sell	1,979 -9,338	-83%	-$1.27M	0.03%	505
2020 Q4	$1.57M	Sell	11,317 -5,133	-31%	-$609K	0.2%	127
2020 Q3	$1.35M	Buy	+16,450	New	+$1.36M	0.17%	186
2020 Q2	–	Sell	-22,207	Closed	-$987K	–	1200
2020 Q1	$987K	Sell	22,207 -4,788	-18%	-$249K	0.13%	216
2019 Q4	$1.15M	Buy	+26,995	New	+$1.11M	0.19%	147

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Aigen Investment Management's RARE Position: Q4 2023 in Review

Aigen Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2023, closing a stake of 6,732 shares — an estimated $240K sold.

Aigen Investment Management first reported a position in RARE in Q4 2019 and held it in 9 quarters. The position peaked at $1.57M in Q4 2020. 237 funds tracked by Wall St. Rank hold RARE as of Q4 2023.

Aigen Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Aigen Investment Management sold 6,732 Ultragenyx Pharmaceutical shares in Q4 2023, an estimated $240K.
Aigen Investment Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 9 quarters.
Aigen Investment Management's Ultragenyx Pharmaceutical position peaked at $1.57M in Q4 2020.
237 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2023.

Based on Aigen Investment Management's 13F filing for Q4 2023, filed 9 Feb 2024.